High-Density Lipoprotein Subclasses and Mild Cognitive Impairment: Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia)1.

BACKGROUND High-density lipoprotein (HDL) containing apolipoprotein A-I is associated with the pathogenesis of Alzheimer's disease (AD). HDL particle size is modified in the presence of pathological conditions, while the significance of the HDL particle size remains controversial. OBJECTIVE The aim of this study was to investigate the HDL lipoprotein subclasses in mild cognitive impairment (MCI) and AD. METHODS This cross-sectional study included 20 AD patients, 17 MCI patients, and 17 age-matched controls without cognitive impairment, selected from the database of the Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia) registry. The diagnoses of AD and MCI were performed by expert neurologists according to the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition criteria. Serum HDL subclasses were measured by electrophoretic separation of lipoproteins using the Lipoprint System. The neutrophil-lymphocyte ratio (NLR), a marker of inflammation, was calculated by dividing the neutrophil count by the lymphocyte count. RESULTS Small-sized HDL particle levels in the MCI group were significantly higher than in the control group, although there was no difference in serum HDL-cholesterol levels between MCI and control groups. NLR in the MCI group was higher than in the control group, but this difference was non-significant (p = 0.09). There was no difference in HDL subclasses or NLR between the AD and control groups. CONCLUSION These findings suggest that HDL subclasses might be associated with the development of MCI.

[1]  T. Hatsukami,et al.  HDL‐3 is a Superior Predictor of Carotid Artery Disease in a Case‐Control Cohort of 1725 Participants , 2014, Journal of the American Heart Association.

[2]  Bruno Vellas,et al.  Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials , 2013, Alzheimer's & Dementia.

[3]  P. Scheltens,et al.  Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[4]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.

[5]  Thomas G. Cole,et al.  Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype , 2000 .

[6]  J. Sicklick,et al.  Neutrophil‐lymphocyte and platelet‐lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma , 2015, Journal of surgical oncology.

[7]  M. Mackness,et al.  Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. , 2015, Gene.

[8]  K. Kotani,et al.  High-density lipoprotein size distribution can differ between subjects with alcoholic and non-alcoholic fatty liver disease. , 2014, Clinical laboratory.

[9]  M. Taskinen,et al.  Effect of HDL composition and particle size on the resistance of HDL to the oxidation , 2010, Lipids in Health and Disease.

[10]  Caiyu Chen,et al.  Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis , 2013, PloS one.

[11]  Shaowu Cheng,et al.  HDL and cognition in neurodegenerative disorders , 2014, Neurobiology of Disease.

[12]  G. Vega,et al.  LDL Phenotype in Subjects with Mild Cognitive Impairment and Alzheimer’s Disease , 2014, Journal of Alzheimer's disease : JAD.

[13]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[14]  S. Young,et al.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. , 1991, The Journal of clinical investigation.

[15]  A. Gugliucci,et al.  Paraoxonase 1 in neurological disorders , 2014, Redox report : communications in free radical research.

[16]  Clinical assessment of cognitive functioning in the aged. , 1983, Psychopharmacology bulletin.

[17]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[18]  J. Ruidavets,et al.  High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. , 2016, Archives of cardiovascular diseases.

[19]  C. Kalogeropoulou,et al.  Advances in high-density lipoprotein physiology: surprises, overturns, and promises. , 2016, American journal of physiology. Endocrinology and metabolism.

[20]  G. Norata,et al.  High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.

[21]  M. Murray,et al.  The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. , 2016, American journal of neurodegenerative disease.

[22]  Z. A. Oztürk,et al.  The Evaluation of Neutrophil-Lymphocyte Ratio in Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[23]  T. Asada,et al.  Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline , 2015, Alzheimer's & dementia.

[24]  M. Dobiášová,et al.  Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. , 2005, Physiological research.

[25]  C. Buhmann,et al.  Characterization of four lipoprotein classes in human cerebrospinal fluid. , 2001, Journal of lipid research.

[26]  T. Asada,et al.  Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial , 2017, EBioMedicine.

[27]  I Litvan,et al.  The FAB: A frontal assessment battery at bedside , 2000, Neurology.

[28]  D. Catalucci,et al.  Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.

[29]  L. Opie,et al.  Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution , 2016, Lipids in Health and Disease.

[30]  Xiao-lin Li,et al.  HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort , 2016, Scientific Reports.

[31]  M. Benson,et al.  Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[32]  C. Wellington,et al.  High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. , 2014, Cell metabolism.

[33]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[34]  Shunichiro Shinagawa,et al.  Differentiation between amnestic‐mild cognitive impairment and early‐stage Alzheimer's disease using the Frontal Assessment Battery test , 2011, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[35]  K. Kotani,et al.  The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. , 2012, Metabolism: clinical and experimental.

[36]  C. Rowe,et al.  An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation , 2014, Journal of Neuroimmunology.

[37]  J. Dietschy Central nervous system: cholesterol turnover, brain development and neurodegeneration , 2009, Biological chemistry.

[38]  M. Emul,et al.  Neutrophil and platelet to lymphocyte ratios in people with subjective, mild cognitive impairment and early Alzheimer's disease , 2017, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[39]  H. Matsuda,et al.  An easy Z-score imaging system for discrimination between very early Alzheimer's disease and controls using brain perfusion SPECT in a multicentre study , 2007, Nuclear medicine communications.

[40]  T. Kudo,et al.  Association between CAG repeat length in the PPP2R2B gene and Alzheimer disease in the Japanese population , 2011, Neuroscience Letters.

[41]  Yucheng Chen,et al.  The Value and Distribution of High-Density Lipoprotein Subclass in Patients with Acute Coronary Syndrome , 2014, PloS one.